GlassScriptPhysician profile
Kelli Gevas
NPI 1528124880
$922.51
in general payments reported to CMS, 2019-2025
14 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2023: $207 · 2024: $327 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.50 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $293.71 | 2021-2025 | Veozah |
| Novo Nordisk INC | $156.08 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $92.96 | 2021-2025 | |
| Currax Pharmaceuticals LLC | $89.67 | 2023-2025 | Contrave, Nexlizet, Nexletol |
| Lilly USA, LLC | $82.26 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Corcept Therapeutics | $37.27 | 2024 | Korlym |
| Vivus LLC | $36.39 | 2024 | Qsymia, Pancreaze |
| Pfizer INC. | $34.40 | 2024 | |
| Exeltis, USA INC. | $29.92 | 2025 | Slynd |
| Hologic Sales and Service, LLC | $14.79 | 2023 | Aptima, Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $14.67 | 2021 | |
| Aspira Women'S Health INC | $14.47 | 2021 | |
| Organon LLC | $14.26 | 2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Gevas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.